BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 10, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2008

View Archived Issues

Sirion and Bridge enter agreement for topical ophthalmic drugs containing norketotifen

Read More

Novel HDAC8-specific inhibitor profiled at Pharmacyclics

Read More

GSK received CHMP positive opinion for H5N1 influenza vaccine

Read More

Fusion protein shows promise as influenza vaccine in preclinical studies

Read More

Schering-Plough: Q4 and full-year 2007 highlights

Read More

Inhibition of QseC signaling, a potential new strategy against tularemia infection

Read More

Novel agents for metabolic disorders reported in recent patent literature

Read More

Elan reviews recent pipeline developments

Read More

Positive preclinical results of S-0139 in ischemic stroke

Read More

FDA accepts and grants priority review to Eurand's NDA for Zentase for pancreatitis

Read More

FDA accepts for review Forest and Cypress' NDA for milnacipran for fibromyalgia

Read More

FDA cancels February 2008 Advisory Committee meeting to discuss Theravance's telavancin

Read More

GPC outlines development plans for its oncology program

Read More

Hyperion Therapeutics begins enrollment in phase II trial of Ammonul for hepatic encephalopathy

Read More

HVTN to initiate phase IIa human trials of GeoVax's DNA and MVA HIV/AIDS vaccines

Read More

InteKrin Therapeutics initiates phase IIb study of INT-131 in type 2 diabetes

Read More

Sciele enters three-year agreement with sanofi-aventis to market Allegra in the U.S.

Read More

Recent patents disclose novel therapeutics for arthritis

Read More

GlaxoSmithKline patent describes new agents for diabetes and related disorders

Read More

Marillion and Cytokine enter license agreement for Pilobuc buccal insert for xerostomia

Read More

Argenta initiates phase II ADC-4022 trial in COPD and severe asthma

Read More

First patient treated with anticancer drug TRC-102 in phase I trial

Read More

Patient recruitment finalized for Moberg Derma's phase III K-101 trial

Read More

PBT-2 shows safety and tolerability in patients with early Alzheimer's disease

Read More

EMEA accepts MAA for tolvaptan in worsening heart failure and hyponatremia

Read More

FDA accepts Duramed's Lo Seasonique NDA for filing

Read More

PX-478 is effective in preclinical mouse model of human lung cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 9, 2025.
  • Red dollar sign under microscope

    Medline plans record-setting $5.37B IPO

    BioWorld MedTech
    Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing